(TEVA) Teva Pharma Industries - Ratings and Ratios

Teva Pharmaceutical Industries Ltd is a global pharmaceutical company that develops, manufactures, and markets generic and proprietary medicines, as well as biopharmaceutical products. With a presence in the US, Europe, Israel, and internationally, the company has a diverse portfolio of products, including generic medicines in various dosage forms, sterile products, and proprietary products such as BENDEKA, TREANDA, COPAXONE, AJOVY, AUSTEDO, and UZEDY, which cater to various therapeutic areas, including CNS, respiratory, and oncology.

The companys product portfolio is complemented by its active pharmaceutical ingredients and contract manufacturing services, as well as its out-licensing platform, which offers a range of products to other pharmaceutical companies. Teva has collaboration agreements with several companies, including MedinCell S.A., Sanofi, Alvotech, and Biolojic Design Ltd., and has a license agreement with MODAG GmbH, demonstrating its commitment to partnerships and innovation.

From a technical analysis perspective, TEVAs stock price is currently at $17.25, with a 20-day SMA of $17.24, indicating a stable short-term trend. The 50-day SMA is at $15.74, suggesting a longer-term uptrend. However, the 200-day SMA is at $17.53, indicating a potential resistance level. The ATR is at 0.69, representing a 3.99% daily volatility. Given the current technical setup, its likely that TEVAs stock price will experience a short-term consolidation phase, potentially between $16.50 and $18.00.

Fundamentally, TEVA has a market capitalization of $19.79 billion and a forward P/E ratio of 6.64, indicating a relatively low valuation compared to its peers. However, the companys RoE is currently negative at -21.36%, suggesting that it is facing significant challenges in terms of profitability. Considering the fundamental data and the technical analysis, our forecast is that TEVAs stock price will experience a moderate increase in the next 6-12 months, driven by potential catalysts such as new product approvals, partnerships, or improvements in profitability. A potential target price could be around $20-22, representing a 15-25% increase from current levels.